Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen pharmacokinetics study with dextromethorphan phenotyping after rifampicin arm cancellation
NL-OMON38337Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dextromethorphan, tamoxifen and rifampicin in breast cancer, sponsored by Erasmus MC. Started Mar 2011; status: active, not recruiting.
02
Drugs
dextromethorphantamoxifenrifampicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON38337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38337.